UPDATE 1-FDA reviewers flag concerns over Sarepta's gene therapy for muscle-wasting disorder

(Adds details in paragraphs 2 and 3) May 10 (Reuters) - Data presented for Sarepta Therapeutics Inc's experimental gene therapy for a muscle-wasting disorder did not provide unambiguous evidence that the treatment worked, the U.S. Food and Drug Administration's staff reviewers on Wednesday.

The company is seeking accelerated approval for the first gene therapy for Duchenne muscular dystrophy, based on data that showed it helped patients make a mini version of the dystrophin protein needed to keep muscle cells intact.

"Additionally, FDA has safety concerns related to the possibility of administering an ineffective gene therapy," the reviewers said in the briefing documents, ahead of a meeting of outside advisers to the drug agency on Friday.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)

Reuters

Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.

off-the-wire

UPDATE 1-FDA reviewers flag concerns over Sarepta's gene therapy for muscle-wasting disorder

By Reuters

Reuters

Reuters

'Unseen' forces moving a lot of gold back to the U.S.? What's really happening – Josh Phair

Gold’s rally teeters as demand falls in China and India, silver faces further downside risk – Heraeus

DeCarley Trading’s Carley Garner, sees gold topping out like it did in 2011

Gold prices are being driven by flows and central banks, not macro and investors: Here’s how to tell – IG

Trade wars: This is how much the U.S. is spending on mineral imports from Canada

off-the-wire

UPDATE 1-FDA reviewers flag concerns over Sarepta&apos;s gene therapy for muscle-wasting disorder

By Reuters

Reuters

Reuters

UPDATE 1-FDA reviewers flag concerns over Sarepta's gene therapy for muscle-wasting disorder